Home › CADASIL › NCT04753970
Retina is a Marker for Cerebrovascular Heath
Retinal Vasoreactivity is a Marker for Cerebral Small Vessel Disease Progression
Who can join
Ages 18 and older · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * Age ≥18 yo. * Diagnosis of CADASIL, sporadic WMD or lobar CMB and age-matched healthy controls (eg. patient's spouse or unrelated friends without SVD) Exclusion Criteria: * Age\<18yo * Pregnant * Breast feeding * Unable to follow commands * Unable to tolerate MRI
About the study
Cerebral small vessel disease (SVD), present in 80-94% of adults over age 65 years, increases the risk of stroke by 2-fold, and dementia by 2.3-fold. There is currently no treatment to slow SVD progression. This study aims to test whether impaired cerebral and retinal vasoreactivity may serve as biomarker for SVD progression, and to evaluate the safety and efficacy of cilostazol (antiplatelet agent with vasodilatory and anti-inflammatory properties) for the treatment of SVD.
What is being tested
- Cilostazol (drug)
Sponsor: Mayo Clinic · Participants: 100 · Started: Feb 9, 2021
Contact the study team
- Meredith McDonald · Phone: 904-953-4200
Official record on ClinicalTrials.gov — NCT04753970
Locations in the U.S.
| Florida | Mayo Clinic Florida, Jacksonville |
Conditions
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.